NSCI Nanalysis Scientific Corp.
Nanalysis Scientific Corp. develops, manufactures, and sells magnetic resonance technology products in Canada, the United States, Europe, Asia, and internationally. The company operates through the Scientific Equipment and Security Services segment. It offers nuclear magnetic resonance (NMR) spectrometers; magnetic resonance test, and measurement and diagnostic system; a 60-NMR platform; 100-NMR platform; 60-TEACH; QUAD NMR Console; and the Cameleon 4 console, a compact alternative to facilitate MRI for teaching. The company also provides software products, such as NMRGui, a user interface for data acquisition and processing of benchtop NMR products; SPINit MR software platform to facilitate data acquisition, processing, and pulse programming; and NMRFx platform that offers a suite of software tools to streamline and automate MR data analysis and management. In addition, it offers security services, including preventive and on-call maintenance services, scheduled preventative maintenance work, corrective maintenance work, installation and upgrade projects for detection and general security equipment; other technical maintenance services; and installation and maintenance services for commercial security equipment, such as scanning devices, metal detectors, detection equipment, and other general security equipment. It serves pharmaceutical, biotechnology, nutraceutical, education, chemical, security, food, oil and gas, materials, life science, medical, and educational industries. Nanalysis Scientific Corp. is headquartered in Calgary, Canada.…
Industry Peers
Scientific & Technical InstrumentsKey Statistics
About Nanalysis Scientific (CVE: NSCI)
›
Nanalysis Scientific (CVE: NSCI) is listed on the TSX Venture Exchange, where its shares trade in CAD. It belongs to the Scientific & Technical Instruments industry, part of the Technology sector.
The shares were at 0.1050 CAD on 19 November 2026, down 48.8% over 52 weeks. Its 52-week range is 0.1000 CAD to 0.2250 CAD: the price is 53.3% below the high and 5.0% above the low.
Its market capitalisation is 14.64M CAD.
Nanalysis Scientific reports return on equity of -42.2%, an operating margin of -5.0% and revenue up 1.5% year over year.
Its debt exceeds its cash by 13.42M CAD, a debt-to-equity ratio of 1.31. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. The next earnings report is expected on 23 November 2026.